
-
Eton Pharmaceuticals NasdaqGM:ETON Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Location: 21925 W. Field Parkway, Deer Park, IL, 60010-7278, United States | Website: https://www.etonpharma.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
520M
Cash
17.42M
Avg Qtr Burn
N/A
Short % of Float
2.84%
Insider Ownership
5.17%
Institutional Own.
53.05%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZONISADE (Zonisamide) (ET-104) Details Rare genetic disease, Neurological disorder | Approved Update | |
Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100) Details Itchy Eyes Associated with Allergies | Approved Quarterly sales | |
ALKINDI® SPRINKLE (hydrocortisone) Details Adrenocortical Insufficiency (Pediatrics) | Approved Quarterly sales | |
Carbaglu® (carglumic acid tablets) Details Hyperammonemia NAGS deficient, chronic hyperammonemia | Approved Quarterly sales | |
EPRONTIA (Topiramate Oral Solution) (ET-101) Details Tonic-clonic seizures / seizures / migraine | Approved Quarterly sales | |
Cysteine hydrochloride injection (generic - ANDA) Details Additive to amino acid solutions to meet the nutritional requirements of newborn infants | Approved Quarterly sales | |
Rezipres (Ephedrine Injection) (ET-203) Details Injectable hospital-use product | Approved Quarterly sales | |
KHINDIVI™ (hydrocortisone) Oral Solution Details Pediatric Adrenocortical Insufficiency | Approved Quarterly sales | |
Nitisinone Capsules Details Tyrosinemia type 1, Rare diseases | Approved Quarterly sales | |
Biorphen® (phenylephrine HCI) Details Hypotension (vasodilation in the setting of anesthesia) | Approved Quarterly sales | |
ET-600 Details Diabetes insipidus | NDA Acceptance for review | |
Dehydrated Alcohol Injection (DS-100) Details Methanol poisoning | Failed Discontinued | |
Lamotrigine Oral Suspension (ET-105) Details Seizures, Epilepsy, Lennox-Gastaut syndrome | Failed Discontinued |